Cidara Therapeutics Soars 10.7% on Promising Influenza Trial Results

On June 24, 2025, Cidara Therapeutics' stock surged by 10.7% in pre-market trading, reflecting significant investor optimism and market confidence in the company's recent developments.

Cidara Therapeutics has seen a substantial increase in its stock price, driven by positive results from its NAVIGATE trial. The trial, which focuses on influenza treatment, has shown promising topline results, leading to a surge in investor interest and stock performance.

The company's CD388 drug candidate has demonstrated strong efficacy in influenza treatment, contributing to the overall positive market sentiment. This development has been a key factor in the company's stock price appreciation over the past year.

Additionally, Cidara Therapeutics has announced a proposed public offering of common stock, which is expected to provide the company with additional capital to support its ongoing research and development efforts. This move has been well-received by investors, further boosting the stock price.